Analysts' Actions -- Bristol-Myers, Merck, United Technologies and More

RATINGS CHANGES

Ambac (AMBC) was downgraded to sell from neutral at MKM Partners. $10 price target. The company is facing increased regulatory scrutiny, MKM said. 

Bristol-Myers Squibb (BMY) was upgraded to buy at Jefferies. $69 price target. The company has an attractive clinical pipeline, but trades at a discount to its peers, Jefferies said. 

Blackstone (BX) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: BX.

Dexcom (DXCM) was upgraded to outperform from perform at Oppenheimer. $84 price target. The company is focused on big, long-term opportunities, Oppenheimer said. 

Merck (MRK) was downgraded to underperform at Jefferies. $48 price target. Earnings estimates are below consensus, as Keytruda should continue to face pressure, Jefferies said. 

Realogy (RLGY) was upgraded to outperform from neutral at Wedbush. $32 price target. The company is trading at a depressed valuation and is leveraged to rising existing home sales, Wedbush said. 

United Technologies (UTX) was upgraded to outperform from neutral at Credit Suisse. $125 price target. Profit margin and earnings momentum are near a bottom, Credit Suisse said. 

Williams (WMB) was upgraded to overweight from equal-weight at Morgan Stanley. $35 price target. Business has stabilized and management should now focus on the cost of capital, Morgan Stanley said. 

This article was written by a staff member of TheStreet.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Complying With GDPR Could Be Costly for Facebook, Google and Other Tech Giants

Complying With GDPR Could Be Costly for Facebook, Google and Other Tech Giants

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation